Akash Mourya | Health and Medicine Advances | Best Researcher Award

Published on by New Scientists

Mr. Akash Mourya | Health and Medicine Advances | Best Researcher Award

PhD Scholar | National Institutes of Pharmaceutical Education and Research | India

Mr. Akash Mourya is a promising young pharmacologist specializing in pharmacology and toxicology, with a strong research focus on liver pathophysiology, hepatoprotective drug discovery, and molecular mechanisms underlying hepatic and pulmonary disorders. His ongoing Ph.D. work at NIPER Mohali builds on extensive preclinical and translational research conducted at the Institute of Liver and Biliary Sciences (ILBS), New Delhi, where he has developed expertise in animal models of liver diseases, hemodynamic studies, and hepatic cell culture systems. His research contributions have advanced understanding of non-alcoholic and alcoholic fatty liver diseases, hepatopulmonary and porto-pulmonary hypertension, and liver regeneration mechanisms. He has co-authored seven peer-reviewed publications in high-impact journals, including Journal of Hepatology, JHEP Reports, American Journal of Physiology–Gastrointestinal and Liver Physiology, npj Gut and Liver, ACS Omega, and Life Sciences. His work has collectively received 31 citations, 7 Documents, with an h-index of 3, reflecting growing recognition within the biomedical research community. In addition to journal articles, Mr. Akash Mourya has contributed two book chapters published by Springer Nature (2024) and Academic Press (2025), covering topics such as oxidative stress and pharmacological interventions in liver disease, and PPARγ signaling in diabetes. His research abstracts have been presented at prestigious international conferences, including the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL). His work integrates pharmacological innovation, molecular biology, and experimental therapeutics, with emphasis on Ayurvedic formulations, CB2 receptor agonists, and novel siRNA nanoparticle delivery systems. Mr. Akash Mourya’s ongoing efforts contribute to translational R&D for liver protection and regeneration, aligning with India’s growing emphasis on integrative pharmacology and precision medicine.

Profiles: Scopus | Google Scholar | ResearchGate | PubMed 

Featured Publications

1. Baweja, S., Kumari, A., Negi, P., Tomar, A., Tripathi, D. M., Mourya, A. K., Rastogi, A., Subudhi, P. D., Thangariyal, S., Kumar, G., Kumar, J., Sood, A., Vashistha, C., Bihari, C., Maiwall, R., & Sarin, S. K. (2023). Hepatopulmonary syndrome is associated with low sphingosine-1-phosphate levels and can be ameliorated by the functional agonist fingolimod. Journal of Hepatology, 79(1), 167–180.

2. Juneja, P., Rahman, S. N. R., Jakhar, D., Mourya, A. K., Tripathi, D. M., Kaur, I., Tiwari, V., & others. (2023). Recombinant VEGF-C (Cys156Ser) improves mesenteric lymphatic drainage and gut immune surveillance in experimental cirrhosis. JHEP Reports, 5(10), 100816.

3. Biswas, S., Yadav, N., Juneja, P., Mourya, A. K., Kaur, S., Tripathi, D. M., & Chauhan, V. S. (2022). Conformationally restricted dipeptide-based nanoparticles for delivery of siRNA in experimental liver cirrhosis. ACS Omega, 7(41), 36811–36824.

4. Kaur, I., Juneja, P., Tiwari, R., Vasudevan, A., Mourya, A. K., Trauner, M., Sarin, S. K., & Tripathi, D. M. (2024). Secondary bile acids in portal blood contribute to liver regeneration in a rat model of partial hepatectomy. American Journal of Physiology – Gastrointestinal and Liver Physiology, 327(4), G645–G658.

5. Tripathi, D. M., Singh, P., Mourya, A. K., & Kaur, S. (2024). Oxidative medicine and novel pharmacological treatment approaches in liver disease. In Adaptation under stressful environments through biological adjustments and interventions (pp. 311–334). Springer Nature.

 

Jie Wu | Health and Medicine | Best Researcher Award

Published on by New Scientists

Prof. Dr. Jie Wu | Health and Medicine | Best Researcher Award

Professor and Lab Director, Shantou University Medical College, China

Prof. Dr. Jie Wu is a Distinguished Professor and Director of the Laboratory of Brain Function and Disease at Shantou University Medical College, China, and formerly served as Professor and Director of the Neurophysiology Laboratory at the Barrow Neurological Institute (BNI), St. Joseph’s Hospital and Medical Center, USA. He earned his M.D. from Xuzhou Medical College in 1983 and Ph.D. in Neurophysiology from Sun Yat-sen University of Medical Sciences in 1990, followed by postdoctoral fellowships at Tohoku University School of Medicine, Japan (1993–1994), and the University of New Mexico, USA (1994–1997). His research focuses on the physiology and pharmacology of nicotinic acetylcholine receptors (nAChRs), molecular mechanisms of epilepsy, and neurodegenerative disorders related to amyloid beta (Aβ) and receptor dysfunction, as well as ATP-sensitive potassium (KATP) channel regulation. Over three decades, he has led groundbreaking neuroscience research funded by the U.S. National Institutes of Health (NIH), the State of Arizona, and various international foundations, making fundamental discoveries in synaptic receptor signaling and neurodegeneration. His pioneering contributions have led to nearly 200 peer-reviewed publications, five book chapters, and eight patents (four U.S. and four Chinese), providing novel insights into receptor-mediated neurological diseases and translational therapies. Among his many honors, Prof. Dr. Jie Wu has received the China National Natural Science Award and the International HH Rosenfield Rekate Pioneer Award, and was listed among the World’s Top 2% Scientists (2022) and elected as a Fellow of the Royal Society of Arts (FRSA, UK, 2024). He serves as Editor-in-Chief and editorial board member for leading international journals and is active in global neuroscience and biomedical societies. With 161 documents, 5,887 citations and an h-index of 44, Prof. Dr. Jie Wu exemplifies research excellence and leadership, advancing global neuroscience through innovation, collaboration, and mentorship that continues to shape the future of brain science and human health worldwide.

Profile: Scopus | ORCID | Google Scholar | ResearchGate | Sci Profiles | Loop | LONGDOM | LinkedIn 

Featured Publications

1. Zhang, X. X., Gao, M., Liu, Q. R., Bi, G. H., Li, X., Yang, H. J., Gardner, E. L., & Wu, J. (2014). Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proceedings of the National Academy of Sciences of the United States of America, 111(46), E5007–E5015.

2. Liu, Q., Huang, Y., Xue, F., Simard, A., DeChon, J., Li, G., Zhang, J., Lucero, L., & Wu, J. (2009). A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. Journal of Neuroscience, 29(4), 918–929.

3. Wang, T. N., Yang, W., Wang, Y., Nagaraj, V. J., Liu, Q., & Wu, J. (2012). Label-free measuring and mapping of binding kinetics of membrane proteins in single living cells. Nature Chemistry, 4(10), 846–853.

4. Chen, D. J., Gao, M., Gao, F. F., Su, Q. X., & Wu, J. (2017). Brain cannabinoid receptor 2: Expression, function and modulation. Acta Pharmacologica Sinica, 38(3), 312–316.

5. Okada, Y. C., Wu, J., & Kyuhou, S. (1997). Genesis of MEG signals in a mammalian CNS structure. Electroencephalography and Clinical Neurophysiology, 103(4), 474–485.